SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that President Trump will push for federal marijuana rescheduling, potentially boosting the bottom lines of cannabis businesses. The community is buzzing with excitement, anticipating a major run similar to past declassification talks. Some are also discussing target price adjustments, and potential short squeezes.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors digest the company's earnings report and forward guidance, with community sentiment split between bullish expectations for new ATHs and concerns about potential profit-taking. Discussions revolve around the impact of AI chip revenue and gross margins on the stock's valuation. Analyst target price upgrades are anticipated, adding to the bullish outlook for some traders.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss the potential of Pemvidutide, particularly after FDA AI acceptance for MASH biopsies, which some believe de-risks the asset. Community members are debating the drug's efficacy, safety profile, and potential for a bidding war, while also addressing concerns and FUD spread by bearish voices. Some traders express optimism about upcoming data and potential buyout scenarios, while others highlight risks and past disappointments.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors discuss its recent earnings report, which featured strong international growth offsetting weaker sales in the Americas, and a surprise announcement that the CEO will be stepping down in 2026. A new share buyback program is adding to the bullish sentiment, while analysts are updating their target prices, leading to community speculation about the company's future direction and potential for new leadership.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading day, with community members discussing a potential pump and dump scheme following a recent reverse split and subsequent offering. The stock's price experienced a significant surge and then a sharp decline, leading to debates about the company's fundamentals and market manipulation. Traders are actively speculating on whether MIGI can regain compliance with listing requirements and if further dilution is expected.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

$HOOD is trending amid discussions about November's trading activity and its potential impact, with a specific focus on slowed trading volumes.  The community is debating if this dip is a buying opportunity or a sign of a larger downturn, while also watching for upcoming events and catalysts. Bullish sentiment remains due to expansion plans and potential AI developments, yet concerns persist around Bitcoin correlation and potential market manipulation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it showcases its in-house autonomy and AI technology at its first-ever Autonomy and AI Day, with community members discussing the potential impact of new AI-driven features and hardware on the company's future. Investors are weighing Rivian's strategy to develop its own chips and compete with Tesla's autonomous driving capabilities, while some express concerns about the timeline for implementation and the capital expenditure required. There are mixed opinions about the stock's potential, with some anticipating a significant rise and others remain cautious given the company's current financial position.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL is trending due to a recently announced national retail distribution agreement with Walmart, sending the stock soaring in premarket trading. Community discussions revolve around the potential for a significant short squeeze and the long-term implications of this deal for the company's brand recognition and revenue. Some traders are wary of potential profit-taking and the stock's history of volatility, while others remain optimistic about further gains.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining attention for its high transaction throughput and compliance-ready architecture, positioning it as a potential backbone for the global financial system. The community is discussing its integration with Bridge, a Stripe company, which facilitates connections to regulated banking streams. Keeta's focus on speed, compliance, and interoperability distinguishes it in the Layer 1 space, attracting interest from investors and institutions alike.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors discuss potential impacts from a shift in US-China tech trade policy regarding chip exports, as well as a new partnership with Tata Electronics in India. Community perspectives are mixed, with some anticipating a rise to previous levels and others remaining skeptical amid broader market dynamics and concerns about potential competitive disadvantages. Discussions also include analyst target price updates and speculation about large options positions influencing near-term price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Predictive Oncology Inc. (POAI) drew significant interest from retail investors after the company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million, which will support its adoption of a digital asset treasury strategy.The firm stated that the principal holding will be the native utility token of the Aethir ecosystem.The two private transactions are expected to close on or about October 2. The funds will be used to support the company’s digital asset treasury strategy, for the acquisition of ATH in the open market, and for working capital and general corporate purposes, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-inc-announces-private-placements-344-million">stated</a>.Last week, Predictive Oncology also <a href="https://stocktwits.com/news-articles/markets/equity/predictive-oncology-shares-tumble-on-reverse-stock-split-announcement/chDl1r4R3IR">announced</a> a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, which became effective at 12:01 a.m. on Tuesday, Sept. 30, 2025. The split is designed to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange. Following the split, the company lowered its shares of common stock to 762,000 from over 11.4 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of Dec. 31, 2024, and a stockholders' deficit of approximately $1.7 million.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spotify-stock-is-slipping-2-in-premarket/chDDP1nR3Bg">Why Spotify Stock Is Slipping 2% In Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.

Equity

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.


Shares of Predictive Oncology Inc. (POAI) tumbled 19% on Thursday after the company announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock.The reverse stock split will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156239/37244/en/Predictive-Oncology-Announces-1-for-15-Reverse-Stock-Split.html">become</a> effective at 12:01 a.m. on Tuesday, September 30, the company said. The reverse stock split is primarily aimed at bringing the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the bourse.At the effective time of the reverse stock split, every 15 shares of Predictive Oncology’s issued and outstanding common stock will be combined automatically into one share of common stock. While the company currently has over 11.4 million shares of common stock, it will be reduced to about 762,000 after the split, the firm added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_2_16_32_PM_png_9c3fdd1117.webp" alt="POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock will fall below $0.50 before the reverse stock split becomes effective.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/629988968</stembedurl>Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders' deficit of approximately $1.7 million.POAI stock is up 17% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiziana-life-sciences-stock-rises-on-advancing-second-asset/chDl0MtR34z">Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

Shares of Predictive Oncology Inc. (POAI) fell to their lowest level in a month on Thursday, drawing&nbsp;significant retail attention. Renovaro announced that its 2025 lawsuit to enforce a merger agreement with POAI will proceed on an expedited trial schedule.Renovaro, a TechBio company specializing in diagnostics and genetically enhanced cancer therapies, said the Delaware Court of Chancery approved its motion to fast-track a&nbsp;lawsuit filed earlier this month.&nbsp;Predictive Oncology shares closed down 10.1% at $0.98 on Thursday, holding steady in after-hours trading.The case stems from an alleged breach of a binding merger agreement signed on Jan. 1.According to Renovaro’s complaint, the agreement required POAI to merge into Renovaro in exchange for a new class of preferred stock.&nbsp;Renovaro claims that Predictive Oncology violated exclusivity and good faith clauses by raising $545,000 in a public offering in February and attempting to terminate the agreement unilaterally in April.The company&nbsp;now seeks specific performance, injunctive relief, and damages for the alleged breaches.In its Form 10-Q filing dated May 14, Predictive Oncology said that while the two companies entered into a binding letter of intent for the merger on Jan. 1, and extended the agreement’s termination date to March 31, no definitive purchase agreement was signed by that date.&nbsp;Predictive Oncology’s board notified Renovaro on April 3 that merger discussions were discontinued and that the company has no further obligations under the letter of intent or extension agreement.&nbsp;The company dismissed Renovaro’s lawsuit as without merit and said it intends to “vigorously” contest the case.The dispute unfolds as Predictive Oncology continues to promote its use of AI and machine learning in drug discovery, citing access to a biobank of over 150,000 live tumor samples.&nbsp;The company said its platform modeled tumor responses for 21 previously untested compounds.On Stocktwits, retail sentiment was ‘bullish’ amid a 2,200% surge in 24-hour message volume.One retail user said they held no position in POAI but were invested in Renovaro and hoped the merger would be completed.&nbsp;<stembedurl>https://stocktwits.com/Stengaard1/message/615590359</stembedurl>Another user suggested POAI could deliver unexpected gains, predicting the stock might rally suddenly.<stembedurl>https://stocktwits.com/EarlofLondon/message/615526666</stembedurl>The stock has risen 6.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish

Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Predictive Oncology Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

POAI
Predictive Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest POAI News

POAIPredictive Oncology Inc